Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanyu Jieyou Capsule is a Traditional Chinese Medicine (TCM) pharmaceutical product developed and manufactured by Guangdong Liye Pharmaceutical Co., Ltd. It is specifically indicated for the treatment of mild to moderate depression. The active ingredient is a standardized extract of *Hypericum perforatum* (St. John's Wort), which contains bioactive compounds such as hypericin and hyperforin. The drug's primary mechanism of action involves the non-selective inhibition of the reuptake of monoamine neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA), in the central nervous system. By increasing the synaptic availability of these neurotransmitters, it helps to regulate mood and emotional stability. It was approved by the China National Medical Products Administration (NMPA) and is often utilized as a natural alternative to synthetic selective serotonin reuptake inhibitors (SSRIs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guanyu Jieyou Capsule.